The emergence of drugs like copyright and Semaglutide signifies a remarkable shift in how we manage blood sugar. These groundbreaking therapies belong to a class known as GLP-1 target agonists, which duplicate the effects of a natural hormone that manages sugar levels and appetite. Initially, developed for diabetes, their effectiveness in supportin